Takeda acquires license for GI motility disorders medication for $15M: 5 things to know

Takeda Pharmaceutical and Theravance Biopharma have entered into a global license, development and commercialization agreement.

Here are five things to know:

1. The agreement centers on TD-8954, a selective 5-HT4 receptor agonist.

2. TD-8954 is being investigated for treatment of gastrointestinal motility disorders, including enteral feeding intolerance.

3. TD-8954 has already received FDA fast-track designation for short-term use to achieve early nutritional adequacy in critically ill patients at high nutritional risk with EFI.

4. Theravance Biopharma will receive an upfront cash payment of $15 million for TD-8954.

5. The company will also receive success-based development and sales milestone payments as well as royalties on global net sales of the product.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Learning Opportunities

Featured Webinars

Featured Whitepapers

Featured Podcast